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SUSTAINED EFFICACY OF INTRA-ARTICULAR FX006 IN A RAT MODEL OF
OSTEOARTHRITIS
A. Kumar 1, A.M. Bendele 2, R.C. Blanks 1, N. Bodick 1. 1 Flexion Therapeutics,
Woburn, MA, USA; 2Bolder BioPATH, Boulder, CO, USA
Purpose: To develop a localized rat knee streptococcal peptidoglycan-
polysaccharide (PGPS) model of osteoarthritis and to evaluate the efﬁcacy
of single intra-articular (IA) doses of FX006, a sustained release formula-
tion of triamcinolone acetonide (TCA) in poly(lactic-co-glycolic acid)
(PLGA) microspheres and Kenalog-40, a crystalline suspension of TCA.
Methods: The PGPS model was modiﬁed to induce localized knee osteo-
arthritis with synovitis and assess prolonged duration of efﬁcacy. Synovitis
was induced in the right knees of 75 rats with injection of PGPS twoweeks
prior to treatment with a single IA injection of FX006 on Day 1 (TCA in
PLGA microspheres), Kenalog, or vehicle. Three ﬂares of synovitis were
induced with tail vein injections of PGPS on Days 1 (2.5 hours after IA
dosing), and subsequently on Days 14 and 28 (with no further dosing with
treatments). FX006 was administered at doses of 0.28, 0.12 or 0.03 mg TCA
and Kenalog at 0.06 mg (which provides overall TCA exposure compa-
rable to FX006 at 0.28 mg; AUCw 350 ng.hr/mL). Differences in weight-
bearing and gait (as a measure of knee pain), histopathology, pharmaco-
dynamics (serum corticosterone) and plasma pharmacokinetics (PK) were
characterized.
Results: As shown in the Figure, upon each reactivation of synovitis,
vehicle-treated animals demonstrated a period of impaired gait (Note:
higher scores indicate greater impairment). Animals injected with a single
IA dose of 0.28 mg FX006 on Day 1 demonstrated signiﬁcant improvement
in gait scores through all three reactivations induced on Days 1, 14, and 28.
Animals injected with 0.06 mg of Kenalog on Day 1 demonstrated
signiﬁcant improvement in gait scores through the 1st reactivation, dimi-
nution of effect in the 2nd reactivation and absence of effect in the 3rd
reactivation. FX006 demonstrated dose-dependence in the magnitude and
duration of effect (data not shown). Though the total amount of TCA in the
high dose of FX006 is approximately 5X the amount in the Kenalog
injection, the Cmax at this dose was 1/10th, and systemic exposure
comparable to that provided by the Kenalog injection (the Cmax in
Kenalog-treated animals of 17 ng/mL was also greater than that reported
following the labeled 40 mg IA dose in patients). Histopathological eval-
uation of the knees taken at the end of the study demonstrated dose
dependent, statistically signiﬁcant improvement by FX006 in the
composite histological score and each component score (inﬂammation,
pannus, cartilage damage and bone resorption) with scores approximating
normal tissue architecture at the high and mid-dose of FX006. All treat-
ment groups had similar corticosterone levels at baseline that were
initially inhibited following both Kenalog and FX006 treatment, but
recovered by Day 14.
ĂConclusions: In a modiﬁed PGPS model of localized knee osteoarthritis in
rats, the prolonged release of TCA from PLGA microspheres following
a single IA injection of FX006 resulted in extended duration of efﬁcacy and
a signiﬁcant improvement in histological scores of joint tissues compared
to Kenalog administered at a dose providing comparable exposure.FX006 produced these effects with low systemic exposure and without
prolonged inhibition of the HPA axis.
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COMPLIANCE WITH THROMBOPROPHYLAXIS USING AN ORAL FACTOR
XA INHIBITOR RIVAROXABAN AFTER TOTAL HIP AND KNEE
ARTHROPLASTY. IS ORAL THERAPY BETTER? AN EXAMINATION OF
THE NON-ADHERENCE RATE OF RIVAROXABAN
S. Rodriguez-Elizalde 1,2, J. Murnaghan 2,1, D. Murnaghan 2, H. Razmjou 2,
J. Gollish 2. 1 Sunnybrook Hlth.Sci. Ctr., Toronto, ON, Canada; 2Univ. of
Toronto, Toronto, ON, Canada
Introduction: Post-operative thrombo-prophylaxis is believed to reduce
the perioperative risk for patients following total hip and knee arthro-
plasty. The non-adherence rate in the literature for patients completing
their prescribed course of traditional thrombo-prophylaxis varies from 5-
40%. Newer oral thrombo-prophylatic agents are now available (factor Xa
inhibitors), however their patient compliance rate is unknown. This study
compares the compliance rate of a prescribed oral factor Xa inhibitor,
Rivaroxaban, for the thrombo-prophylaxis of post-operative hip and
knee arthroplasty patients and compares it to the established literature
compliance rates of other modalities. The non-adherent patients were
then subgroup analysed to examine for non-compliant patient risk factors.
Methods: Since January 2010, an on going prospective database for all total
joint replacement surgeries has followed patients treated with thrombo-
prophylaxis post-operatively. As a standard of care, a self-administered
questionnaire is recorded at the six-week mark. This includes information
about the medication used for thrombo-prophylaxis, the prescription
administration, compliance and complications from therapy. The compli-
ance of their prescribed fourteen-day therapy was then calculated and
compared to the published literature compliance rates of other thrombo-
prophylaxis agents. A sub-group analysis was then undertaken of the non-
adherence (NA) group.
Results: A total of 1789 patients (1343 total knees and 947 total hips)
received a prescription for Rivaroxaban post-operatively. Of these, 53
(3.0%) did not complete their six-week follow up questionnaire. Another
52 (2.9%) stated they did not complete the entire course of prescribed
therapy. The overall compliance rate of those given a prescription is 97.1%.
If we assume all those lost to follow-up did not complete their prescribed
course, the compliance drops to 94.1%, leaving a non-adherence (NA) rate
of 5.9% for Rivaroxaban.
The group of stated non-adherent patients were more likely to be female
(71.2% vs 60.1%, p¼0.03), and were trending to have a higher BMI (30.6 vs
28.9, p¼0.08). Age was not a factor for either group. Four patients who
were NA encountered bleeding complications, compared to 18 in the
compliant group (7.5% vs 1.1% p¼0.01).
Discussion: This study demonstrates that patients are more likely to
complete a thrombo-prophylaxis regime on an oral Factor Xa inhibitor
than other therapies. The stated NA rate of prescribed Rivaroxaban is 2.9%.
Assuming all those lost to follow-up were non-adherent, the calculated
overall NA rate would be 5.9%. This compares favourably to the non-
adherence rates of injectable low molecular weight, which has multiple
published series demonstrating NA of 5-40%, and most recently, a large
multi-center series of 1315 patients showing a NA of 20.8%. This study
demonstrates that the prescription of rivaroxaban affords a superior
patient compliance compared with subcutaneous LMWH.
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MCP-1 AND RANTES LEVELS IN THE SINOVIUM OF OSTEOARTHRITIC
PATIENTS ARE REDUCED AFTER TREATEMENT WITH CHONDROITIN
SULFATE BUT NOT WITH PARACETAMOL
P. Escudero 1,2, L. Tío 3, L. Piqueras 1, C. Company 1,2, M. Sanz 1,2,
J. Monfort 4. 1Dept. of Pharmacology Univ. of Valencia, Valencia, Spain;
2Univ.ry Clinic Hosp. Res. Fndn.-INCLIVA, Univ. of Valencia, Valencia, Spain;
3 FIMIM, Barcelona, Spain; 4 Parc de Salut Mar, Barcelona, Spain
Purpose: The aim of this study was to investigate the clinical conse-
quences and the levels of chemokines in OA patients treated either with
chondroitin sulphate (CS) or paracetamol.
